Through continuous research and development of new solutions, our strive to meet the changing needs of customers and contribute to the progress of various industries.

Synthetic CBD substitutes are assured easier to purify than plant extracts

Synthetic CBD substitutes are easy to purify

Synthetic CBD substitutes are easier to purify than plant extracts, eliminating the need for marijuana cultivation in farmland and avoiding legal complications related to marijuana products. This work was recently published in the journal ‘Scientific Reports’.

It is safer than CBD, with no potential for abuse, and there is no need to cultivate marijuana, “said Mark Mascal, a professor of chemistry at the University of California, Davis. Mascal’s laboratory at the University of California, Davis, collaborated with researchers from the University of Reading in the UK to carry out this work

Products containing Synthetic CBD have recently gained popularity due to their so-called health effects, and because the compound does not cause high concentrations. CBD has also been studied as a drug compound for treating diseases such as anxiety, epilepsy, glaucoma, and arthritis. However, due to its origin in cannabis or extracts from cannabis plants, CBD has legal issues in certain state and federal laws. CBD can also be chemically converted into tetrahydrocannabinol (THC), an intoxicating compound in cannabis.

8,9-dihydrocannabinol (H2CBD) is a synthetic molecule with a structure similar to CBD. Mascal’s laboratory has developed a simple method for synthesizing H2CBD cheaply from commercially available chemicals. Unlike CBD, there is no way to convert H2CBD into intoxicating THC, “he said.

Synthetic CBD
Synthetic CBD

One important medical use of cannabis and CBD is to treat epilepsy. The US Food and Drug Administration has approved extracts of herbal CBD for the treatment of some seizures, and animal studies also have strong evidence.

Researchers tested the synthesis of H2CBD targeting herbal CBD in rats with induced seizures. H2CBD and CBD were found to be equally effective in reducing the frequency and severity of seizures.

Mascal is collaborating with colleagues from the University of California, Davis School of Medicine to conduct more animal research, with the goal of entering the clinical trial phase as soon as possible. The University of California, Davis has applied for a temporary patent for the anti seizure use of H2CBD and its analogues, and Mascal has established a company Syncanica to continue development.

So our company has been committed to developing CBD intermediate products. CAS: 504-15-4 3187-58-4 2524-37-0 4299-72-3102342-60-9 500-49-2 55382-52-0 21855-51-6 46113-76-2 102342-62-1500-66-3 58016-28-7 38862-65-65465-20-3 102342-63-2500-67-4 6121-77-3 38862-66-7 46733-28-2 102342-64-3, achieving tonnage levels from one carbon atom to 10 carbon atoms.

Leave Us A Message